Source: Virtual Congress 2021 – Biology of lung cancer: preclinical and translational research



Rating:

Share or cite this content

Citations should be made in the following way:
A. Gründing (Hannover, Germany), B. Martinez-Delgado (Madrid, Spain), B. Liu (Hannover, Germany), D. Deluca (Hannover, Germany), S. Wrenger (Hannover, Germany), T. Welte (Hannover, Germany), S. Janciauskiene (Hannover, Germany). Lipid-related anti-cancer drug resistance of lung adenocarcinoma cells. 1118

Member's Comments

No comment yet.

Related content which might interest you: The selection of candidate microRNA biomarkers of acquired drug resistance in the lung adenocarcinoma cells treated with EGFR TKI Source: International Congress 2019 – Novel molecular pathways in lung cancer and COPD Year: 2019 New chemotherapeutic agents Source: ISSN=1025-448x, ISBN=1-904097-18-9, page=259 Year: 2001 A possible role of intracellular calcium in the development of anti-cancer therapy -resistance in lung cancer cells Source: Eur Respir J 2006; 28: Suppl. 50, 853s Year: 2006 Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer Source: Eur Respir J 2002; 19: 557-570 Year: 2002 ABCG2 is determinant to SN-38 resistance in non-small cell lung cancer Source: Annual Congress 2005 - Prognostic factors in lung cancer Year: 2005 Relationship between a clinical drug resistance and immunohistochemical expression of P-glycoprotien, multidrug resistance protein, and p53 in small cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 231s Year: 2002 The effect of new drug-resistance antisense gene on multidrug resistance mechanism of drug-resistant human small cell lung cancer cells Source: Eur Respir J 2007; 30: Suppl. 51, 715s Year: 2007 HIF-1α modulation by topoisomerase inhibitors in A549, a non-small cell lung cancer cell line Source: Annual Congress 2007 - Biology in thoracic oncology Year: 2007 Extracts of lung cancer cells reveal antitumour antibodies in sera of patients with lung cancer Source: Eur Respir J 2003; 21: 342-346 Year: 2003 Dynamic monitoring of plasma DAMP proteins during various anticancer agents in advanced lung cancer patients Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer Year: 2020 Second-line combination therapies in nonsmall cell lung cancer without known driver mutations Source: Eur Respir Rev 2015; 24: 582-593 Year: 2015 Relationship between mutated P53 and the acquired multi-drug resistance after cisplatin selection in NCI-H460 cell line of human large cell lung cancer Source: Annual Congress 2004 - Molecular biology Year: 2004 Adaptation to hypoxia leads to apoptosis resistance to cisplatin in non-small cell lung cancer (NSCLC) cell line Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008 Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010 The biology of lung cancer Source: ISSN=1025-448x, ISBN=1-904097-18-9, page=61 Year: 2001 High CO2 tumor microenvironment confers chemoresistance in lung cancer cells. Source: International Congress 2017 – Lung cancer: latest basic research on molecular alterations, tumour-immune system-microenvironment interplay and the metabolome Year: 2017 Roles of volume-sensitive Cl- channel in cisplatin resistance of human lung adenocarcinoma cells Source: Annual Congress 2010 - Pathology of lung cancer Year: 2010 Prx1 provides resistance to docetaxel-induced apoptosis in lung cancer cells Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 Microscopic vessel invasion and visceral pleural invasion are correlated with EMT, cancer stemness and resistance to therapy in lung adenocarcinoma Source: International Congress 2016 – Lung cancer immunology: latest research Year: 2016